Kalvista Pharmaceuticals Inc (KALV)

03:43 AM

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace

03:43 AM

Apr 02, 2025

KalVista Strengthens Team with Strategic 87,000-Share Option Grant Package - Stock Titan

Apr 02, 2025

Apr 01, 2025

Where are the Opportunities in (KALV) - news.stocktradersdaily.com

Apr 01, 2025

Mar 31, 2025

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph

Mar 31, 2025

Mar 31, 2025

KalVista Set for Key Investor Presentation: What to Expect from Needham Conference - Stock Titan

Mar 31, 2025

Mar 27, 2025

KONFIDENT-KID trial of sebetralstat is now fully enrolled - Angioedema News

Mar 27, 2025

Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Kalvista shares By Investing.com - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial - Yahoo Finance

Mar 26, 2025

Mar 26, 2025

Stifel maintains Buy on Kalvista stock, price target steady at $39 By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Stifel maintains Buy on Kalvista stock, price target steady at $39 - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Kalvista shares - Investing.com

Mar 26, 2025

Mar 26, 2025

Kalvista stock holds as JMP reiterates $19 target By Investing.com - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Bank of New York Mellon Corp - Defense World

Mar 26, 2025

Mar 26, 2025

Kalvista stock holds as JMP reiterates $19 target - Investing.com

Mar 26, 2025

Mar 25, 2025

KalVista completes enrollment for pediatric HAE trial By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial - MarketScreener

Mar 25, 2025

Mar 25, 2025

KalVista completes enrollment for pediatric HAE trial - Investing.com India

Mar 25, 2025

Mar 25, 2025

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial - MarketScreener

Mar 25, 2025

Mar 25, 2025

Breakthrough Pediatric HAE Drug Trial Hits Major Milestone: Patient Demand Surges 50% - Stock Titan

Mar 25, 2025

Mar 25, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $23.80 Average Target Price from Analysts - Defense World

Mar 25, 2025

Mar 21, 2025

(KALV) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 21, 2025

Mar 17, 2025

H.C. Wainwright maintains Buy on Kalvista, $20 target By Investing.com - Investing.com Canada

Mar 17, 2025

Mar 17, 2025

KalVista Pharmaceuticals’ (KALV) Buy Rating Reiterated at HC Wainwright - Armenian Reporter

Mar 17, 2025

Mar 17, 2025

H.C. Wainwright maintains Buy on Kalvista, $20 target - Investing.com India

Mar 17, 2025

Mar 17, 2025

KalVista Pharmaceuticals Stock (KALV): Advancements in HAE Treatment and Regulatory Progress - Value the Markets

Mar 17, 2025

Mar 16, 2025

HC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World

Mar 16, 2025

Mar 15, 2025

Needham & Company LLC Reiterates “Buy” Rating for KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World

Mar 15, 2025

Mar 13, 2025

Buy Rating for KalVista Pharmaceuticals Driven by Anticipated FDA Approval and Strong Market Position - TipRanks

Mar 13, 2025

Mar 13, 2025

Sebetralstat provides early, fast relief for HAE attacks: Data - Angioedema News Today

Mar 13, 2025

Mar 13, 2025

Jefferies cuts Kalvista stock price target to $31 from $33 - Investing.com

Mar 13, 2025

Mar 13, 2025

Jefferies cuts Kalvista stock price target to $31 from $33 By Investing.com - Investing.com Canada

Mar 13, 2025

Mar 13, 2025

KalVista Pharmaceuticals Advances Sebetralstat for HAE - TipRanks

Mar 13, 2025

Mar 12, 2025

KalVista Pharmaceuticals, Inc. SEC 10-Q Report - TradingView

Mar 12, 2025

Mar 12, 2025

Kalvista Pharmaceuticals Inc reports results for the quarter ended January 31Earnings Summary - TradingView

Mar 12, 2025

Mar 12, 2025

KALVISTA PHARMACEUTICALS Earnings Results: $KALV Reports Quarterly Earnings - Nasdaq

Mar 12, 2025

Mar 12, 2025

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - Business Wire

Mar 12, 2025

Mar 12, 2025

Reviewing KalVista Pharmaceuticals (NASDAQ:KALV) and Hillstream BioPharma (NASDAQ:HILS) - Defense World

Mar 12, 2025

Mar 11, 2025

KalVista Pharmaceuticals CEO sells $79,827 in stock By Investing.com - Investing.com Australia

Mar 11, 2025

Mar 10, 2025

KalVista Pharmaceuticals CEO sells $79,827 in stock - Investing.com

Mar 10, 2025

Mar 10, 2025

KalVista Pharmaceuticals CEO Sells Shares to Cover Tax Obligations - TradingView

Mar 10, 2025

Mar 10, 2025

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema - The Bakersfield Californian

Mar 10, 2025

Mar 07, 2025

Kalvista Pharmaceuticals Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView

Mar 07, 2025

Mar 05, 2025

JMP Securities sets $19 target for Kalvista Pharmaceuticals stock - MSN

Mar 05, 2025

Mar 05, 2025

JMP reiterates Kalvista stock with $19 target, sees market growth - MSN

Mar 05, 2025